FDA Declines to Approve Generic Version of Advair Diskus––for Now

Mylan keeps reason for rejection under wraps

Mylan has reported on the status of its abbreviated new drug application with the FDA for its generic version of GlaxoSmithKline’s Advair Diskus (fluticasone propionate and salmeterol inhalation powder). The company states that it has received a complete response letter (CRL) from the FDA and is in the process of reviewing the agency’s comments.

Mylan provided no details regarding the FDA’s concerns or how long the product might be delayed.

The CRL has given GlaxoSmithKline additional time to sell Advair Diskus without competition from a cheaper generic. According to Reuters, Advair has generated more than $1 billion in sales each year since 2001.

Another generic version of Advair––from Hikma Pharmaceuticals––is awaiting an FDA approval decision by May 10.

Sources: Mylan(link is external); March 29, 2017; and Reuters(link is external); March 29, 2017.

More Headlines

Single-Tablet Dolutegravir / Rilpivirine Regimen Submitted to FDA

First two-drug HIV maintenance treatment

Why Antibiotics Fail

Biologists seek to correct flaw in how bacterial susceptibility is tested

As Government-Funded Cancer Research Sags, Scientists Fear U.S. Is Losing Its Edge

Trump budget aims to cut $1 billion from NCI

Conservative Groups Push HHS Secretary Price to Help Dismantle PPACA

Price urged to wield regulatory powers as senators flounder

New Health Care Plan Unlikely This Year, Republican Senator Says

Conservative and centrist GOP lawmakers continue to butt heads

Researchers Develop New Drug-Delivery Strategy for Pain Relief

“Game-changing” approach targets receptors inside nerve cells

FDA Approves Rebinyn for Adults and Children With Hemophilia B

Product launch expected in first half of 2018

Study: More Than Half of Cancer Patients’ Emergency Department Visits Appear Preventable

Findings represent rare opportunity to reduce costs and improve patient outcomes, authors say

HHS: Mylan May Have Overcharged U.S. for EpiPen by $1.27 Billion

Amount is three times more than company agreed to repay

Paul Lendner

Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweisen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.